Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoko Takebe

Showing results (61-70 of 140) with videos related to

Pageof 14
Sort By:
Investigational New Drugs|August 8, 2019
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumorsMark N Stein, Susan Goodin, Murugeson Gounder, et al.
Journal of the National Cancer Institute|December 13, 2012
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizersYaacov Richard Lawrence, Bhadrasain Vikram, James J Dignam, et al.
Expert Opinion on Drug Delivery|April 6, 2017
Drug delivery of oral anti-cancer fluoropyrimidine agentsKoh Miura, Hiroshi Shima, Naoko Takebe, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2025
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumorsSusan C Scott, Anna Farago, W Victoria Lai, et al.
Cancer Research Communications|September 17, 2025
RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer TypesZahra Davoudi, Thomas S Dexheimer, Nathan P Coussens, et al.
Cancer|April 28, 2011
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinomaHeather D Brooks, Bonnie S Glisson, B Nebiyou Bekele, et al.
Journal of Clinical Pharmacology|March 31, 2022
Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid TumorsEmily J Koubek, Andrew T Ralya, Thomas R Larson, et al.
Lancet (London, England)|August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsDai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer InstituteDai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2013
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium studyAmar Gajjar, Clinton F Stewart, David W Ellison, et al.
Pageof 14

Showing results (61-70 of 140) with videos related to

Sort By:
Pageof 14
Investigational New Drugs|August 8, 2019
A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumorsMark N Stein, Susan Goodin, Murugeson Gounder, et al.
Journal of the National Cancer Institute|December 13, 2012
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizersYaacov Richard Lawrence, Bhadrasain Vikram, James J Dignam, et al.
Expert Opinion on Drug Delivery|April 6, 2017
Drug delivery of oral anti-cancer fluoropyrimidine agentsKoh Miura, Hiroshi Shima, Naoko Takebe, et al.
Cancer Chemotherapy and Pharmacology|February 25, 2025
A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumorsSusan C Scott, Anna Farago, W Victoria Lai, et al.
Cancer Research Communications|September 17, 2025
RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer TypesZahra Davoudi, Thomas S Dexheimer, Nathan P Coussens, et al.
Cancer|April 28, 2011
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinomaHeather D Brooks, Bonnie S Glisson, B Nebiyou Bekele, et al.
Journal of Clinical Pharmacology|March 31, 2022
Population Pharmacokinetics of Z-Endoxifen in Patients With Advanced Solid TumorsEmily J Koubek, Andrew T Ralya, Thomas R Larson, et al.
Lancet (London, England)|August 14, 2022
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trialsDai Chihara, Ruitao Lin, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2022
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer InstituteDai Chihara, Erich P Huang, Shanda R Finnigan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2013
Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium studyAmar Gajjar, Clinton F Stewart, David W Ellison, et al.
Pageof 14